Current and future treatment of amyloid neuropathies. (December 2014)

• Record Type: Journal Article
• Authors: Adams, David; Cauquil, Cecile; Theaudin, Marie; Rousseau, Antoine; Algalarrondo, Vincent; Slama, Michel S
• Is Part Of: Expert review of neurotherapeutics. Volume 14:Number 12(2014)
• Page Start: 1437
• Page End: 1451
• Publication Date: 2014-12
• Subjects: Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1586/14737175.2014.983905
• Languages: English
• ISSNs: 1473-7175

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Amyloid neuropathies of acquired or genetic origin are disabling and life-threatening, until recently there were few treatment options available. Poor prognosis is related to progressive neuropathy and associated, although often underdiagnosed, cardiac involvement in specific transthyretin (TTR) gene mutations. Recent progress has modified prognosis and management of amyloid neuropathies. In TTR-familial amyloidosis with polyneuropathy, major changes have occurred over the last 30 years: better knowledge concerning genetics, phenotypes and epidemiology, and the advent of possible treatments. Liver transplantation, first performed in 1990, stopped disease progression, thus doubling survival in early onset V30M patients. More recently tetramer stabilizers (Tafamidis and Diflunisal) showed a significant reduction of progression of neuropathic scores; Tafamidis is now recommended in Stage I patients. Two multicentric clinical trials are now ongoing to evaluate TTR gene silencing by antisense Oligonucleotides (ASO) or siRNA. In the near future we should have new therapeutical options for patients with amyloid neuropathy.</p> </abstract>